Sun Pharmaceuticals Industries Limited

Our first research center, Sun Pharma Advanced Research Center (SPARC), was set up in 1993 in Baroda in the western state of Gujarat in India. The work done here was instrumental for the rapid growth at Sun Pharma. Starting from a small base, the infrastructure at this initially 32,000 sq ft research center was used to streamline product development to bring to market on an average 40 formulations and 25 new API every year. These facilities have since been shifted to our new research campus. In 2004, a new research campus with areas for process / product development went on stream in Baroda . His Excellency, Dr. A P J Abdul Kalam, the Hon. President of India , formally inaugurated this research center in a glittering ceremony in December 2004. This 16-acre campus with nearly 330,000 sq ft research area offers space for the development of generics meeting international development standards, including difficult to make complex generics and complex API processes, such as those for steroids and peptides. A second research center in Mumbai, spread over 50,000 sq ft of floor area, develops generics for the developed markets. Our research commitment for 2009-10 is between 7-8% of the company's turnover and we've put in a total of Rs. 15 billion for research since 1993. Our approach to research has been incremental starting with the simple and moving on to the more complex. We began with simpler dosage forms, then moved on to novel drug delivery systems and complex API. Across areas, 76 patents have been received of 233 patents filed. Every year, we typically bring about 40 new products to the Indian market, scale up 25 API, develop and file for 30 plus ANDAs for the US and 8-10 DMFs for US / Europe

Dilip S. Shanghvi : Chairman and Managing Director

 

Sudhir V. Valia : Executive Director

 

Sailesh T. Desai : Executive Director

 

S. Kalyanasundaram : Chief Executive Officer

 

Hasmukh S. Shah: Non-Executive Independent Director

 

Keki M. Mistry: Non-Executive Independent Director

 

Ashwin Dani: Non-Executive Independent Director

 

S. Mohandchand Dadha: Non-Executive Independent Director

 

At our 8 world-class locations, all of which are ISO 14001 and ISO 9002 approved We have put in place the infrastructure and procedures to support a stringent quality policy. All our systems are well documented and are implemented by an expert trained staff with a line of reporting that is independent of manufacturing. We are committed to ensure that every product we manufacture and distribute meets with and conforms over its shelf life to internationally accepted standards of quality, purity, efficacy and safety. At each manufacturing site, the latest analytical instruments and tightly monitored quality assurance and quality control systems ensures consistent quality of our products. The quality team at each manufacturing site is guided by a Corporate Quality Unit (CQU). This CQU has members from quality assurance, quality engineering, quality control, and regulatory affairs. CQU regularly updates location-based quality representatives on new regulatory practices and monitors the quality of documentation in order to comply with changing international requirements.

 

With worldclass technology and a team of strong professionals, we have built sites and systems that meet the most stringent international manufacturing standards. Expert quality teams ensure that systems and processes remain in compliance with the latest standards. A number of our plants hold approvals from the USFDA and the UK MHRA. APIs and Dosage forms are made in 19 sites across India, US, Hungary and Bangladesh.

1983

Sun Pharma begins operations in Kolkata with 5 psychiatry - based products, first with 2 people and then with a 10 - employee team. Year 1 turnover - Rs. 1 million. Within a year, the marketing effort is expanded to cover all eastern states. A compact manufacturing facility for tablets/capsules is set up at Vapi.


1986

Administrative office is set up in Mumbai. Customer coverage extends to select cities in Western India.


1987

Marketing operations are rolled out nation-wide.


1988

With the launch of the brands Monotrate and Angizem, the first few cardiology products are launched. We feature for the first time in a market audit by the prescription tracking company, ORG at rank 107th with 0.1% market share.


Top 1989

The corporate office is shifted to Baroda, in the western state of Gujarat. Products used in gastroenterology are introduced. Exports to neighbouring countries begin.


1991

Construction begins at the first research center SPARC (Sun Pharma Advanced Research center), with 46,000 sq ft of research space, and investments of almost the size of that year's profits. The company's turnover is Rs. 9.74 cr, and market rank is 70th.

At Sun Pharma, we are committed to creating a continually replenished pipeline of speciality generics, included differentiated generics, and registering these across markets. Our research projects are geared to enable us develop the latest molecules and bring them to market, at a reasonable cost. Focused development of generics in defined speciality areas and creating difficult to mimic generics based on complex technologies, is key to our efforts. Our first research center, Sun Pharma Advanced Research Center (SPARC), was set up in 1993 in Baroda in the western state of Gujarat in India. The work done here was instrumental for the rapid growth at Sun Pharma. Starting from a small base, the infrastructure at this initially 32,000 sq ft research center was used to streamline product development to bring to market on an average 40 formulations and 25 new API every year. These facilities have since been shifted to our new research campus. In 2004, a new research campus with areas for process / product development went on stream in Baroda . His Excellency, Dr. A P J Abdul Kalam, the Hon. President of India , formally inaugurated this research center in a glittering ceremony in December 2004. This 16-acre campus with nearly 330,000 sq ft research area offers space for the development of generics meeting international development standards, including difficult to make complex generics and complex API processes, such as those for steroids and peptides. This site houses 168 labs that address different aspects of generic dosage form and API development. A full fledged bioequivalence center spread over 25,000 sq ft and fully equipped with 222 beds works on biostudies for submissions in India and international markets.